FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3088379519> ?p ?o ?g. }

• W3088379519 abstract "Abstract Background Tumours in mammary glands represent the most common neoplasia in bitches, as in humans. This high incidence results in part from the stimulation of sex hormones on these glands. Among mammary tumours, inflammatory carcinoma is the most aggressive, presenting a poor prognosis to surgical treatment and chemotherapy. One of the most widely used chemotherapy drugs for breast cancer treatment is doxorubicin (DOXO). Alternative therapies have been introduced in order to assist in these treatments; studies on treatments using stem cells have emerged, since they have anti-inflammatory and immunomodulatory properties. The aim of this study was to evaluate the effects of DOXO and canine amniotic membrane stem cells (AMCs) on the triple-negative canine inflammatory mammary carcinoma cell line IPC-366. Methods Four experimental groups were analysed: a control group without treatment; Group I with DOXO, Group II with AMC and Group III with an association of DOXO and AMCs. We performed the MTT assay with DOXO in order to select the best concentration for the experiments. The growth curve was performed with all groups (I-III) in order to verify the potential of treatments to reduce the growth of IPC-366. For the cell cycle, all groups (I-III) were tested using propidium iodide. While in the flow cytometry, antibodies to progesterone receptor (PR), estrogen receptor (ER), PCNA, VEGF, IL-10 and TGF-β1 were used. For steroidogenic pathway hormones, an ELISA assay was performed. Results The results showed that cells treated with 10 µg/mL DOXO showed a 71.64% reduction in cellular growth after 72 h of treatment. Reductions in the expression of VEGF and PCNA-3 were observed by flow cytometry in all treatments when compared to the control. The intracellular levels of ERs were also significantly increased in Group III (4.67% vs. 27.1%). Regarding to the levels of steroid hormones, significant increases in the levels of estradiol (E2) and estrone sulphate (S04E1) were observed in Groups I and III. On the other hand, Group II did not show differences in steroid hormone levels in relation to the control. We conclude that the association of DOXO with AMCs (Group III) promoted a reduction in cell growth and in the expression of proteins related to proliferation and angiogenesis in IPC-366 triple-negative cells. Conclusions This treatment promoted ER positive expression, suggesting that the accumulated oestrogen conducted these cells to a synergistic state, rendering these tumour cells responsive to ERs and susceptible to new hormonal cancer therapies." @default.
• W3088379519 created "2020-10-01" @default.
• W3088379519 creator A5000712604 @default.
• W3088379519 creator A5023101147 @default.
• W3088379519 creator A5037801579 @default.
• W3088379519 creator A5046934148 @default.
• W3088379519 creator A5049410743 @default.
• W3088379519 creator A5051533048 @default.
• W3088379519 creator A5057380775 @default.
• W3088379519 creator A5061321945 @default.
• W3088379519 creator A5070361730 @default.
• W3088379519 creator A5073776958 @default.
• W3088379519 creator A5084720586 @default.
• W3088379519 date "2020-09-24" @default.
• W3088379519 modified "2023-10-17" @default.
• W3088379519 title "Effects of doxorubicin associated with amniotic membrane stem cells in the treatment of canine inflammatory breast carcinoma (IPC-366) cells" @default.
• W3088379519 cites W1505805985 @default.
• W3088379519 cites W1974738527 @default.
• W3088379519 cites W1981643680 @default.
• W3088379519 cites W1983947402 @default.
• W3088379519 cites W1990279811 @default.
• W3088379519 cites W1997434585 @default.
• W3088379519 cites W1999738495 @default.
• W3088379519 cites W1999795858 @default.
• W3088379519 cites W2000292756 @default.
• W3088379519 cites W2003422299 @default.
• W3088379519 cites W2010292674 @default.
• W3088379519 cites W2027540026 @default.
• W3088379519 cites W2029080338 @default.
• W3088379519 cites W2038974551 @default.
• W3088379519 cites W2039430749 @default.
• W3088379519 cites W2044233644 @default.
• W3088379519 cites W2066400670 @default.
• W3088379519 cites W2071936539 @default.
• W3088379519 cites W2074540988 @default.
• W3088379519 cites W2075468784 @default.
• W3088379519 cites W2077499674 @default.
• W3088379519 cites W2080136595 @default.
• W3088379519 cites W2081839292 @default.
• W3088379519 cites W2084504340 @default.
• W3088379519 cites W2092886186 @default.
• W3088379519 cites W2103038661 @default.
• W3088379519 cites W2104335315 @default.
• W3088379519 cites W2117692326 @default.
• W3088379519 cites W2123899152 @default.
• W3088379519 cites W2125471482 @default.
• W3088379519 cites W2127137750 @default.
• W3088379519 cites W2143408624 @default.
• W3088379519 cites W2149170603 @default.
• W3088379519 cites W2157506743 @default.
• W3088379519 cites W2164159671 @default.
• W3088379519 cites W2523763608 @default.
• W3088379519 cites W2549976854 @default.
• W3088379519 cites W2615453589 @default.
• W3088379519 cites W2623830287 @default.
• W3088379519 cites W2727569417 @default.
• W3088379519 cites W2944433566 @default.
• W3088379519 cites W4235221123 @default.
• W3088379519 doi "https://doi.org/10.1186/s12917-020-02576-0" @default.
• W3088379519 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7513323" @default.
• W3088379519 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32972410" @default.
• W3088379519 hasPublicationYear "2020" @default.
• W3088379519 type Work @default.
• W3088379519 sameAs 3088379519 @default.
• W3088379519 citedByCount "2" @default.
• W3088379519 countsByYear W30883795192022 @default.
• W3088379519 countsByYear W30883795192023 @default.
• W3088379519 crossrefType "journal-article" @default.
• W3088379519 hasAuthorship W3088379519A5000712604 @default.
• W3088379519 hasAuthorship W3088379519A5023101147 @default.
• W3088379519 hasAuthorship W3088379519A5037801579 @default.
• W3088379519 hasAuthorship W3088379519A5046934148 @default.
• W3088379519 hasAuthorship W3088379519A5049410743 @default.
• W3088379519 hasAuthorship W3088379519A5051533048 @default.
• W3088379519 hasAuthorship W3088379519A5057380775 @default.
• W3088379519 hasAuthorship W3088379519A5061321945 @default.
• W3088379519 hasAuthorship W3088379519A5070361730 @default.
• W3088379519 hasAuthorship W3088379519A5073776958 @default.
• W3088379519 hasAuthorship W3088379519A5084720586 @default.
• W3088379519 hasBestOaLocation W30883795191 @default.
• W3088379519 hasConcept C121608353 @default.
• W3088379519 hasConcept C126322002 @default.
• W3088379519 hasConcept C203014093 @default.
• W3088379519 hasConcept C2776694085 @default.
• W3088379519 hasConcept C2781303535 @default.
• W3088379519 hasConcept C28328180 @default.
• W3088379519 hasConcept C3018521938 @default.
• W3088379519 hasConcept C502942594 @default.
• W3088379519 hasConcept C530470458 @default.
• W3088379519 hasConcept C54355233 @default.
• W3088379519 hasConcept C553184892 @default.
• W3088379519 hasConcept C71924100 @default.
• W3088379519 hasConcept C86803240 @default.
• W3088379519 hasConceptScore W3088379519C121608353 @default.
• W3088379519 hasConceptScore W3088379519C126322002 @default.
• W3088379519 hasConceptScore W3088379519C203014093 @default.
• W3088379519 hasConceptScore W3088379519C2776694085 @default.
• W3088379519 hasConceptScore W3088379519C2781303535 @default.
• W3088379519 hasConceptScore W3088379519C28328180 @default.
• W3088379519 hasConceptScore W3088379519C3018521938 @default.

• next